BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27905519)

  • 1. The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
    Guffanti F; Fruscio R; Rulli E; Damia G
    Sci Rep; 2016 Dec; 6():38142. PubMed ID: 27905519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance.
    Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
    Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease.
    Li Y; Kang S; Qin JJ; Wang N; Zhou RM; Sun HY
    Gynecol Oncol; 2012 Sep; 126(3):455-9. PubMed ID: 22683585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
    Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.
    Ocaña A; Pérez-Peña J; Alcaraz-Sanabria A; Sánchez-Corrales V; Nieto-Jiménez C; Templeton AJ; Seruga B; Pandiella A; Amir E
    Oncotarget; 2016 Apr; 7(16):22865-72. PubMed ID: 26992217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
    Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.
    Lorusso D; Cirillo F; Mancini M; Spatti GB; Grijuela B; Ditto A; Raspagliesi F
    Oncology; 2013; 85(2):122-7. PubMed ID: 23941904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
    Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
    Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.
    Shimogai R; Kigawa J; Itamochi H; Iba T; Kanamori Y; Oishi T; Shimada M; Sato S; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2008; 18(3):499-505. PubMed ID: 18476949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.
    Martini P; Paracchini L; Caratti G; Mello-Grand M; Fruscio R; Beltrame L; Calura E; Sales G; Ravaggi A; Bignotti E; Odicino FE; Sartori E; Perego P; Katsaros D; Craparotta I; Chiorino G; Cagnin S; Mannarino L; Ceppi L; Mangioni C; Ghimenti C; D'Incalci M; Marchini S; Romualdi C
    Clin Cancer Res; 2017 May; 23(9):2356-2366. PubMed ID: 27827314
    [No Abstract]   [Full Text] [Related]  

  • 17. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
    BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol analogue (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline induces G₂/M cell cycle arrest through the activation of ATM/ATR in human cervical carcinoma HeLa cells.
    Kim JY; Choi HE; Lee HH; Shin JS; Shin DH; Choi JH; Lee YS; Lee KT
    Oncol Rep; 2015 May; 33(5):2639-47. PubMed ID: 25812484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.
    Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL
    Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer.
    Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z
    Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.